Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
PubMed PMID: 18378004
2-1(3)4/h1-8
is a potent and selective inhibitor of the hedgehog signaling with an IC50 ~46 nM
GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0
Krajka-Kuźniak V
Ipragliflozin 98 phosphate PubMed PMID: 18378004Ipragliflozin, also known as ASP1941, is a potent and selective SGLT2 inhibitor for treatment of type 2 diabetes. Ipragliflozin treatment improved glycaemic control when added to metformin therapy and may be associated with weight loss and reductions in blood pressure compared to placebo. Ipragliflozin improves not only hyperglycemia but also diabetes obesity associated metabolic abnormalities in type 2 diabetic mice. It was approved for use in Japan
US$ 294427.50
US$ 999.50
US$ 1849.50
US$ 2657.00
US$ 4802.00
US$ 20.00